LIGAND PHARMACEUTICALS INC

LGND - CIK 0000886163

Market cap$4.97 B

Rank#1388

SEC filings2,226

LIGAND PHARMACEUTICALS INC trades as LGND and has a market capitalization of $4.97 B, making it the #1388 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $268.09M, up 60.4% from the prior year and net income of $124.45M. This page tracks LIGAND PHARMACEUTICALS INC through 2,226 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$268.09MFY 2025

Net income (latest FY)$124.45MFY 2025

Operating cash flow (latest FY)$49.36MFY 2025

Total assets (latest FY)$1.56BFY 2025

Net margin46.4%latest FY

Financial performance

Over the last 9 fiscal years LIGAND PHARMACEUTICALS INC's revenue grew from $108.97M to $268.09M, a compound annual growth rate of 10.5%. Net profit margin expanded from -1.5% to 46.4% over the same period - every figure below comes from the company's audited annual filings.

LGND annual revenueView details

Key statistics

Market cap: $4.97 B
Share price (derived)market cap / shares outstanding: $247.80
P/E ratio (trailing FY): 39.9
EPS (diluted)FY 2025: $6.13
Shares outstandingas of 2026-05-05: 0.02B
Total equityas of 2026-03-31: $997.32M
Return on equity: 12.5%
Cash & equivalentsas of 2026-03-31: $115.08M

Latest filings

Filing	Type	Filed
Proxy materials	DEFA14A	2026-05-18
Major company event	8-K	2026-05-18
Insider trade	4	2026-05-14
Insider sale notice	144	2026-05-13
Insider sale notice	144	2026-05-12
Quarterly report	10-Q	2026-05-08
Major company event	8-K	2026-05-07
Insider trade	4	2026-05-04

Browse the full filing history (2,226 filings)

Recent press releases

Ligand to Participate in June Investor Conferences2026-05-27
Ligand Pharmaceuticals Incorporated - Ligand to Participate in June Investor Conferences
Ligand Reports First Quarter 2026 Financial Results2026-05-07
Ligand Pharmaceuticals Incorporated - Ligand Reports First Quarter 2026 Financial Results
Ligand to Participate in May Investor Conferences2026-05-05
Ligand Pharmaceuticals Incorporated - Ligand to Participate in May Investor Conferences
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator2026-04-27
Ligand Pharmaceuticals Incorporated - Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand to Report First Quarter 2026 Financial Results on May 7, 20262026-04-22
Webcast: Live and replay webcasts of the call are available here .

Similar companies

The largest companies sharing LIGAND PHARMACEUTICALS INC's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T LGND vs LLY

JNJJohnson & Johnson$573.98 B LGND vs JNJ

ABBVAbbVie Inc.$399.47 B LGND vs ABBV

MRKMerck & Co., Inc.$293.16 B LGND vs MRK

AZNAstraZeneca PLC$286.27 B LGND vs AZN

Frequently asked questions

What is LIGAND PHARMACEUTICALS INC's market cap?

LIGAND PHARMACEUTICALS INC (LGND) has a market capitalization of $4.97 B as of 2026-06-10, ranking #1388 among US-listed companies.

How much revenue does LIGAND PHARMACEUTICALS INC make?

LIGAND PHARMACEUTICALS INC reported revenue of $268.09M for fiscal year 2025, an increase of 60.4% year over year.

Is LIGAND PHARMACEUTICALS INC profitable?

Yes. LIGAND PHARMACEUTICALS INC reported net income of $124.45M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.